Michael F.  DeMane net worth and biography

Michael DeMane Biography and Net Worth

Director of Nevro
Michael DeMane joined us in March 2011 and has served as our Chief Executive Officer and as Executive Chairman. Effective January 1, 2017, Mr. DeMane transitioned to non-executive Chairman of the Board. Mr. DeMane has served on the board of directors of several private companies since 2009, as well as on the board of directors of eResearch Technology, Inc., a public company specializing in contract research clinical services, from July 2008 to April 2012. From March 2009 to June 2010, Mr. DeMane served as a Senior Advisor to Thomas, McNerney & Partners, a healthcare venture firm. Mr. DeMane served as the Chief Operating Officer of Medtronic from August 2007 to April 2008. Prior to his COO role, Mr. DeMane served at Medtronic as Senior Vice President from May 2007 to August 2007, Senior Vice President and President: Europe, Canada, Latin America and Emerging Markets from August 2005 to May 2007, Senior Vice President and President: Spinal, ENT and Navigation from February 2002 to August 2005, and President, Spinal from January 2000 to February 2002. Prior to that, he was President at Interbody Technologies, a division of Medtronic Sofamor Danek, Inc., from June 1998 to December 1999. From April 1996 to June 1998, Mr. DeMane served at Smith & Nephew Pty. Ltd. as Managing Director, Australia and New Zealand, after a series of research and development and general management positions with Smith & Nephew Inc. Mr. DeMane earned a B.S. in Chemistry from St. Lawrence University and an M.S. in Bioengineering from Clemson University.

What is Michael F. DeMane's net worth?

The estimated net worth of Michael F. DeMane is at least $7.33 million as of May 2nd, 2017. Mr. DeMane owns 501,795 shares of Nevro stock worth more than $7,331,225 as of March 28th. This net worth approximation does not reflect any other assets that Mr. DeMane may own. Learn More about Michael F. DeMane's net worth.

How do I contact Michael F. DeMane?

The corporate mailing address for Mr. DeMane and other Nevro executives is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. Nevro can also be reached via phone at (650) 251-0005 and via email at [email protected]. Learn More on Michael F. DeMane's contact information.

Has Michael F. DeMane been buying or selling shares of Nevro?

Michael F. DeMane has not been actively trading shares of Nevro over the course of the past ninety days. Learn More on Michael F. DeMane's trading history.

Who are Nevro's active insiders?

Nevro's insider roster includes Michael DeMane (Director), D. Grossman (CEO), Kevin O'Boyle (Director), Kashif Rashid (General Counsel), and Elizabeth Weatherman (Director). Learn More on Nevro's active insiders.

Are insiders buying or selling shares of Nevro?

During the last twelve months, Nevro insiders bought shares 1 times. They purchased a total of 7,500 shares worth more than $171,600.00. The most recent insider tranaction occured on June, 7th when Director Shawn Mccormick bought 7,500 shares worth more than $171,600.00. Insiders at Nevro own 3.0% of the company. Learn More about insider trades at Nevro.

Information on this page was last updated on 6/7/2023.

Michael F. DeMane Insider Trading History at Nevro

See Full Table

Michael F. DeMane Buying and Selling Activity at Nevro

This chart shows Michael F. Demane's buying and selling at Nevro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nevro Company Overview

Nevro logo
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $14.61
Low: $14.28
High: $14.70

50 Day Range

MA: $15.95
Low: $13.56
High: $19.01

2 Week Range

Now: $14.61
Low: $13.36
High: $39.67

Volume

92,229 shs

Average Volume

484,810 shs

Market Capitalization

$531.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91